You are here

Article Text

Article menu
Download PDFPDF
Review
Genomic testing in high-grade serous ovarian cancer: current options and future development
  1. Michael-John Devlin1,2 and
  2. Rowan Miller2,3
  1. 1 Barts Cancer Institute, Queen Mary University of London, London, UK
  2. 2 Department of Medical Oncology, St Bartholomew’s Hospital, London, UK
  3. 3 Department of Medical Oncology, University College London Hospital, London, UK
  1. Correspondence to Dr Rowan Miller, Medical Oncology, University College London Hospitals NHS Foundation Trust, London, NW1 2PG, UK; rowan.miller{at}ucl.ac.uk

Abstract

Understanding the genomic complexity of high-grade serous ovarian cancer is now essential in guiding patient management, particularly in the first-line setting. Our knowledge in this area has expanded rapidly in recent years, with biomarkers developing in parallel to agents designed to exploit cancer-associated genetic aberrations. In this review we will take stock of the current landscape of genetic testing and look towards the future with developments that aim to refine personalized treatment paradigms and track treatment resistance in real time.

  • Medical Oncology
  • Ovary
  • Cystadenocarcinoma, Serous

https://doi.org/10.1136/ijgc-2022-003702

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @drmjdevlin

    • Contributors Equal contribution to design, literature review and writing of article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests RM: Consultancy from MSD, GSK, AZ, Ellipses, Shionogi, Clovis Oncology and GI Innovation Speaker bureau from Roche, GSK, AZ and Clovis Oncology. Travel grants from AZ and GSK. Trial funding – MSD. M-JD: No disclosures.

    • Provenance and peer review Commissioned; internally peer reviewed.